A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin

Yaqian Zhou,1,* Xingyu Zhu,2,* Shangyang Lin,1 Chenqi Zhu,1 Li Wu,1 Rui Chen,1 Zhipeng Chen,1 Weidong Li1,3 1College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of China; 2Department of Pharmacy and Traditional Chinese Medicine, Jiangsu College of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhou Y, Zhu X, Lin S, Zhu C, Wu L, Chen R, Chen Z, Li W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	xanthatin polydopamine nanoparticles gastric cancer target pharmacokinetics Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/66fe68cc102d4f52b3ac6b218c768b0a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66fe68cc102d4f52b3ac6b218c768b0a
record_format	dspace
spelling	oai:doaj.org-article:66fe68cc102d4f52b3ac6b218c768b0a2021-12-02T08:48:19ZA Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin1178-2013https://doaj.org/article/66fe68cc102d4f52b3ac6b218c768b0a2020-07-01T00:00:00Zhttps://www.dovepress.com/a-novel-nanoparticle-preparation-to-enhance-the-gastric-adhesion-and-b-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Yaqian Zhou,1,* Xingyu Zhu,2,* Shangyang Lin,1 Chenqi Zhu,1 Li Wu,1 Rui Chen,1 Zhipeng Chen,1 Weidong Li1,3 1College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of China; 2Department of Pharmacy and Traditional Chinese Medicine, Jiangsu College of Nursing, Huaian 223001, People’s Republic of China; 3Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of China*These authors contributed equally to this workCorrespondence: Weidong LiEngineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of ChinaEmail liweidong0801@163.comObjective: To prepare xanthatin (XA)-loaded polydopamine (PDA) nanoparticles (PDA-XA-NPs) and to investigate their adhesion and bioavailability.Materials and methods: PDA-XA-NPs were synthesized and characterized using transmission electron microscopy, zeta potential analysis and encapsulation efﬁciency analysis. Their in vitro release kinetics and inhibitory effects on gastric cancer were studied. The adhesion of PDA-XA-NPs was evaluated by in vivo imaging atlas. The pharmacokinetics of PDA-XA-NPs and XA was compared.Results: PDA-XA-NPs had a spherical shape, a particle size of about 380 nm, an encapsulation efficiency of (82.1 ± 0.02) % and a drug loading capacity of (5.5 ± 0.1)%. The release of PDA-XA-NPs in PBS was stable and slow, without being affected by pH. The adhesion capacity of PDA-XA-NPs for mucin was significantly higher than that of bulk drug. The gastric mucosal retention of PDA-XA-NPs reached 89.1% which significantly exceeded that of XA. In vivo imaging showed that PDA-XA-NPs targeting the stomach were retained for a period of time. The pharmacokinetics study showed that PDA-XA-NPs had a longer retention time and a slower drug release than those of XA. In vitro experiments confirmed that PDA-XA-NPs exerted similar inhibitory effects on gastric cancer to those of XA, which lasted for a period of time.Conclusion: High-adhesion NPs were constructed. Gastric cancer was targeted by orally administered PDA-XA-NPs, as a potentially feasible therapy. Eventually, the bioavailability of XA was increased.Keywords: xanthatin, polydopamine, nanoparticles, gastric cancer, target, pharmacokineticsZhou YZhu XLin SZhu CWu LChen RChen ZLi WDove Medical Pressarticlexanthatinpolydopaminenanoparticlesgastric cancertargetpharmacokineticsMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 5073-5082 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	xanthatin polydopamine nanoparticles gastric cancer target pharmacokinetics Medicine (General) R5-920
spellingShingle	xanthatin polydopamine nanoparticles gastric cancer target pharmacokinetics Medicine (General) R5-920 Zhou Y Zhu X Lin S Zhu C Wu L Chen R Chen Z Li W A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin
description	Yaqian Zhou,1,* Xingyu Zhu,2,* Shangyang Lin,1 Chenqi Zhu,1 Li Wu,1 Rui Chen,1 Zhipeng Chen,1 Weidong Li1,3 1College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of China; 2Department of Pharmacy and Traditional Chinese Medicine, Jiangsu College of Nursing, Huaian 223001, People’s Republic of China; 3Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of China*These authors contributed equally to this workCorrespondence: Weidong LiEngineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing 210023, People’s Republic of ChinaEmail liweidong0801@163.comObjective: To prepare xanthatin (XA)-loaded polydopamine (PDA) nanoparticles (PDA-XA-NPs) and to investigate their adhesion and bioavailability.Materials and methods: PDA-XA-NPs were synthesized and characterized using transmission electron microscopy, zeta potential analysis and encapsulation efﬁciency analysis. Their in vitro release kinetics and inhibitory effects on gastric cancer were studied. The adhesion of PDA-XA-NPs was evaluated by in vivo imaging atlas. The pharmacokinetics of PDA-XA-NPs and XA was compared.Results: PDA-XA-NPs had a spherical shape, a particle size of about 380 nm, an encapsulation efficiency of (82.1 ± 0.02) % and a drug loading capacity of (5.5 ± 0.1)%. The release of PDA-XA-NPs in PBS was stable and slow, without being affected by pH. The adhesion capacity of PDA-XA-NPs for mucin was significantly higher than that of bulk drug. The gastric mucosal retention of PDA-XA-NPs reached 89.1% which significantly exceeded that of XA. In vivo imaging showed that PDA-XA-NPs targeting the stomach were retained for a period of time. The pharmacokinetics study showed that PDA-XA-NPs had a longer retention time and a slower drug release than those of XA. In vitro experiments confirmed that PDA-XA-NPs exerted similar inhibitory effects on gastric cancer to those of XA, which lasted for a period of time.Conclusion: High-adhesion NPs were constructed. Gastric cancer was targeted by orally administered PDA-XA-NPs, as a potentially feasible therapy. Eventually, the bioavailability of XA was increased.Keywords: xanthatin, polydopamine, nanoparticles, gastric cancer, target, pharmacokinetics
format	article
author	Zhou Y Zhu X Lin S Zhu C Wu L Chen R Chen Z Li W
author_facet	Zhou Y Zhu X Lin S Zhu C Wu L Chen R Chen Z Li W
author_sort	Zhou Y
title	A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin
title_short	A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin
title_full	A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin
title_fullStr	A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin
title_full_unstemmed	A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin
title_sort	novel nanoparticle preparation to enhance the gastric adhesion and bioavailability of xanthatin
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/66fe68cc102d4f52b3ac6b218c768b0a
work_keys_str_mv	AT zhouy anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT zhux anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT lins anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT zhuc anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT wul anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT chenr anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT chenz anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT liw anovelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT zhouy novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT zhux novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT lins novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT zhuc novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT wul novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT chenr novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT chenz novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin AT liw novelnanoparticlepreparationtoenhancethegastricadhesionandbioavailabilityofxanthatin
_version_	1718398365441458176

A Novel Nanoparticle Preparation to Enhance the Gastric Adhesion and Bioavailability of Xanthatin

Ejemplares similares